The second randomised trial (THYME) did not meet its primary objective of prolonged progression-free survival when AZD8931 was added to weekly paclitaxel in patients with advanced breast cancer and low expression of HER2 (NCT00900627). This evidence concerns the gene ERBB2 and breast carcinoma.